← All countries · Western Pacific
97.0%
MCV1
2025 · Administrative (country-reported)
97.3%
DTP3
2025 · Administrative (country-reported)
97.3%
IPV complete
2025 · Administrative (country-reported)
97.3%
HepB3
2025 · Administrative (country-reported)
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99.3%2025 · Administrative (country-reported) | 99.3% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 97.3%2025 · Administrative (country-reported) | 97.3% | D · poor | |
| IPV1First dose of inactivated polio vaccine | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| IPV completeInactivated polio vaccine, complete primary series | 97.3%2025 · Administrative (country-reported) | 97.3% | D · poor | |
| MCV1First dose of measles-containing vaccine | 97.0%2025 · Administrative (country-reported) | 97.0% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 95.8%2025 · Administrative (country-reported) | 95.8% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 96.9%2025 · Administrative (country-reported) | 96.9% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 97.3%2025 · Administrative (country-reported) | 97.3% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 99.4%2025 · Administrative (country-reported) | 99.4% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 96.9%2025 · Administrative (country-reported) | 96.9% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | 98.1%2025 · Administrative (country-reported) | 98.1% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 96.4%2025 · Administrative (country-reported) | 96.4% | D · poor | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 99.7%2016 · Administrative (country-reported) | 99.7% | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 572025 | 78.9per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02020 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (53 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 1 | M2 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. |
| DTAPIPVDTaP-IPV (acellular) vaccine | 2 | M4 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. |
| DTAPIPVDTaP-IPV (acellular) vaccine | 3 | M6 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | M18 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y5-Y6 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y18 | Risk group(s) | Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M1 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | M2 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M4 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 3 | M6 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 4 | M15 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y10-Y14 | HPV for females only | 2-dose HPV for girls aged 10-14 years. 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV for females only | 2-dose HPV for girls aged 10-14 years. 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | Y15-Y17 | Catch-up children | 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons over 65 years old |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | 2nd dose of MMR is replaced by MMRV at 18 months of age from September 2018 |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Health workers | Adults(>=Y18) born in or after 1970 who have neither been infected with measles nor received one dose of measles vaccine after their 1st birthday. Healthcare workers and full-time students enrolling in local higher education institutions for the first time who are not immune and have not received two doses of measles vaccine after their 1st birthday. Women of childbearing age(Y18 - Y50) with no immune of rubella. | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | >=Y18 | Risk group(s) | Adults(>=Y18) born in or after 1970 who have neither been infected with measles nor received one dose of measles vaccine after their 1st birthday. Healthcare workers and full-time students enrolling in local higher education institutions for the first time who are not immune and have not received two doses of measles vaccine after their 1st birthday. Women of childbearing age(Y18 - Y50) with no immune of rubella. |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M18 | General/routine | 2nd dose of MMR is replaced by MMRV at 18 months of age from September 2018 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | >=Y65 | Adults | Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the vaccination protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will receive PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Starting from September 2024, PCV13 began transitioning to the 15-valent pneumococcal conjugate vaccine (PCV15). By November 2024, PCV13 had been completely replaced by PCV15. For individuals who have received PPSV23 but not PCV15, it is recommended to receive PCV15 one year after PPSV23 vaccination. |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M2 | General/routine | The PCV15 vaccine was introduced in September 2024 to replace all PCV13. |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | >=Y2 | Risk group(s) | Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the vaccination protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will receive PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Starting from September 2024, PCV13 began transitioning to the 15-valent pneumococcal conjugate vaccine (PCV15). By November 2024, PCV13 had been completely replaced by PCV15. For individuals who have received PPSV23 but not PCV15, it is recommended to receive PCV15 one year after PPSV23 vaccination. |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M4 | General/routine | The PCV15 vaccine was introduced in September 2024 to replace all PCV13. |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M6 | General/routine | The PCV15 vaccine was introduced in September 2024 to replace all PCV13. |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 4 | M15 | General/routine | The PCV15 vaccine was introduced in September 2024 to replace all PCV13. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y65 | Adults | Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been provided to chronic patients aged 2 and above and elderly individuals aged 60 and above. Starting September 25, 2023, the vaccination policy was changed to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 and above and elderly individuals aged 65 and above, with the requirement to receive PCV13 first, followed by PPSV23 one year later. Those who have received PPSV23 but not PCV13 need to wait one year after PPSV23 vaccination before receiving PCV13. From September 2024, PCV15 has completely replaced PCV13, while the eligible groups remain unchanged. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y2 | Risk group(s) | Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been provided to chronic patients aged 2 and above and elderly individuals aged 60 and above. Starting September 25, 2023, the vaccination policy was changed to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 and above and elderly individuals aged 65 and above, with the requirement to receive PCV13 first, followed by PPSV23 one year later. Those who have received PPSV23 but not PCV13 need to wait one year after PPSV23 vaccination before receiving PCV13. From September 2024, PCV15 has completely replaced PCV13, while the eligible groups remain unchanged. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women in each pregnancy(between 27-36 weeks); adults(>=Y18) with no vaccination history of pertussis; adults and adolescents(>=Y7) with no vaccination history of DTP and Tdap. | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | >=Y7 | Risk group(s) | Pregnant women in each pregnancy(between 27-36 weeks); adults(>=Y18) with no vaccination history of pertussis; adults and adolescents(>=Y7) with no vaccination history of DTP and Tdap. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | Y7 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. Starting from September 2018, Tdap has replaced Td for the grade 6 vaccination (ages 10 to 14). In certain situations, when children have completed the 5th dose of IPV/OPV before grade 1, Tdap is uesd as the tetanus booster instead of Tdap-IPV. |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y10-Y14 | General/routine | Regarding the 5th dose of DTP-IPV vaccine, for children aged 7 and above, Td was used before September 2018, and Tdap has been used from September 2018 onwards, both administered alongside IPV during grade 1 vaccination. Starting from September 2018, Tdap has replaced Td for the grade 6 vaccination (ages 10 to 14). In certain situations, when children have completed the 5th dose of IPV/OPV before grade 1, Tdap is uesd as the tetanus booster instead of Tdap-IPV. |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 5 | Y7 | General/routine | Since 1 September 2020, all people are given administration of Tdap-IPV. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y22 | Adults | According to vaccine supplity, we use Td or TT as a 10-year booster dose of Tetanus. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | Y32 | Adults | According to vaccine supplity, we use Td or TT as a 10-year booster dose of Tetanus. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | Y42 | Adults | According to vaccine supplity, we use Td or TT as a 10-year booster dose of Tetanus. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | Y52 | Adults | According to vaccine supplity, we use Td or TT as a 10-year booster dose of Tetanus. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | Y62 | Adults | According to vaccine supplity, we use Td or TT as a 10-year booster dose of Tetanus. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y72 | Adults | According to vaccine supplity, we use Td or TT as a 10-year booster dose of Tetanus. |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | 2nd dose of varceilla (MMRV) at 18 months has been introduced from September 2018 |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.